Presentations

15:30

The post-transplant lymphoproliferative disorders metagenomic shotgun microbial sequencing (PTLD-MSMS) study: clinical insights from the full cohort

Vikas Dharnidharka (US)

Bio Abstract

15:40

Phase I Clinical Evaluation of Allogeneic Virus-Specific T Cell Therapy in Solid Organ Transplant Recipients with Refractory Viral Infections

Rajiv Khanna (AU)

Bio Abstract

15:50

Measles immunity before and after solid organ transplantation: evidence for preserved protective neutralizing antibody

Camille N. Kotton (US)

Bio Abstract

16:00

Proximal Tubule-Derived SPP1 Activates Proteotoxic Stress Response and CD8⁺ T Cell Exhaustion in BK Polyomavirus Nephropathy

Yingzhen He (CN)

Bio Abstract

16:07

Virologic clearance with maribavir by baseline cytomegalovirus DNAemia in solid organ transplant recipients: A post hoc analysis of phase 2 and 3 trials

Deepali Kumar (CA)

Bio Abstract

16:14

Comparing the post-omicron transplant impact of SARS-COV2 and other respiratory viral infections

Beatrice Sim (AU)

Bio Abstract

16:21

Real-world effectiveness and safety of maribavir in solid organ transplant recipients with refractory/resistant cytomegalovirus or intolerance to anti-cytomegalovirus drugs: Interim results from the ARISE study

Nassim Kamar (FR)

Bio Abstract

16:26

Real-world CMV hyperimmunoglobulin prophylaxis in heart and lung transplantation: one-year interim results from a prospective multicenter study

Markus Barten (DE)

Bio Abstract

16:31

Real world efficacy of maribavir when used as pre-emptive therapy for cytomegalovirus reactivation in alloHCT patients who are intolerant, refractory or resistant

Violet Zhu (AU)

Bio Abstract

16:36

Donor-Derived Severe Dengue in a Kidney Transplant Recipient Uncovered Pathogenic Neutrophil Inflammation and Protective CD14+ Monocyte Antiviral Programs

Ying Su (CN)

Bio Abstract